Assessing the therapeutic potential of PDE-5 inhibitors in adults: Insights from a multi-omics study
Abstract
Phosphodiesterase-5 inhibitors have beneficial pleiotropic effects and hold promise as adjuvant treatments for cancer, dementia, and other disorders. Sixteen men and women aged 50-60 were administered daily sildenafil/tadalafil for 1 month. We characterized molecular signatures of sildenafil/tadalafil treatment via analyses and multi-omics integration of the serum metabolome and skeletal muscle proteome and transcriptome. In serum, eicosanoids decreased and arginine biosynthesis pathway components increased following sildenafil/tadalafil. In skeletal muscle following sildenafil, blood vessel development and immune response genes increased, indicating augmented angiogenesis and possible inflammation at proximate biopsy sites. Proteins related to telomere maintenance and protein folding increased, suggesting reduced cellular senescence and cellular stress or functional adaptations. In skeletal muscle following tadalafil, there were no differentially expressed genes, and despite reduction of many proteins there were no enriched biological processes. Notably, sildenafil resulted in a more cohesive and substantial molecular signal in skeletal muscle. Multi-omics integration for both treatments revealed significant coexpression patterns. Phosphodiesterase-5 inhibitors showed systemic anti-inflammatory effects, as indicated by reduced serum levels of pro-inflammatory eicosanoids. However, this did not translate to immunohistochemical changes. Additional research is warranted to…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.